The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. | About two and a half years after originating the role ...

He also thinks a big merger would cut across O’Day’s plans, given he is only 15 months into running the company and his strategy is still being played out. Furthermore, Gilead is still working ...